Patient-reported outcomes and daily activity assessed with a digital wearable device in patients with paroxysmal nocturnal hemoglobinuria treated with ravulizumab: REVEAL, a prospective, observational study
This was the first study to use digital monitoring technology to collect data on physical activity and sleep in patients with PNH. The findings indicate that ravulizumab treatment enables patients with PNH to achieve activity levels (heart rate, sleep duration, step count) and quality of life that are comparable to those of the US general population. A weak positive correlation was identified between patient-reported physical and mental health and daily physical activity levels.
Authors
- David Dingli (ORCID: https://orcid.org/0000-0001-7477-3004)
- Karl-Johan Myrén (ORCID: https://orcid.org/0000-0003-2065-2930)
- Yogesh Patel (ORCID: https://orcid.org/0000-0002-8916-5228)
- Elizabeth A. Griffiths (ORCID: https://orcid.org/0000-0002-0288-8248)
- Wei-Nchih Lee
- Jae Min (ORCID: https://orcid.org/0000-0003-4112-9583)
- Jeffrey C. Yu
Institutions
- Roswell Park Comprehensive Cancer Center (US)
- Mayo Clinic (US)
- Evidation Health (United States) (US)
- Alexion Pharmaceuticals (United States) (US)
- Mayo Clinic in Florida (US)
- AstraZeneca (United States) (US)
Publication Details
- Journal
- Health and Quality of Life Outcomes
- Published
- 2024-08-09
- DOI
- https://doi.org/10.1186/s12955-024-02279-2
- Citations
- 3
- Primary Topic
- Complement system in diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.72
Funders
- AstraZeneca
- Alexion Pharmaceuticals